151 related articles for article (PubMed ID: 9337685)
21. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
Culy CR; Spencer CM
Drugs; 2001; 61(5):641-84. PubMed ID: 11368288
[TBL] [Abstract][Full Text] [Related]
22. Amifostine for protection from antineoplastic drug toxicity.
Foster-Nora JA; Siden R
Am J Health Syst Pharm; 1997 Apr; 54(7):787-800. PubMed ID: 9099346
[TBL] [Abstract][Full Text] [Related]
23. Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse.
Shaw LM; Bonner HS; Brown DQ
Drug Metab Dispos; 1994; 22(6):895-902. PubMed ID: 7895607
[TBL] [Abstract][Full Text] [Related]
24. New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion.
Bonner HS; Shaw LM
J Clin Pharmacol; 2002 Feb; 42(2):166-74. PubMed ID: 11831539
[TBL] [Abstract][Full Text] [Related]
25. Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Semin Oncol; 2002 Dec; 29(6 Suppl 19):2-8. PubMed ID: 12577236
[TBL] [Abstract][Full Text] [Related]
26. Amifostine: chemotherapeutic and radiotherapeutic protective effects.
Santini V
Expert Opin Pharmacother; 2001 Mar; 2(3):479-89. PubMed ID: 11336600
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of WR-2721 and carboplatin.
Budd GT; Ganapathi R; Bauer L; Murthy S; Adelstein D; Weick J; Gibson V; McLain D; Sergi J; Bukowski RM
Eur J Cancer; 1993; 29A(8):1122-7. PubMed ID: 8390844
[TBL] [Abstract][Full Text] [Related]
28. Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro.
Fulda S; Oster W; Berthold F
Anticancer Drugs; 1997 Jan; 8(1):34-41. PubMed ID: 9147609
[TBL] [Abstract][Full Text] [Related]
29. Intraduodenal administration of ethiofos (WR-2721): dose proportionality study in the rhesus monkey.
Geary RS; Swynnerton NF; Miller MA; Mangold DJ; Ludden T
Res Commun Chem Pathol Pharmacol; 1989 Aug; 65(2):147-59. PubMed ID: 2555852
[TBL] [Abstract][Full Text] [Related]
30. Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action.
Grdina DJ; Shigematsu N; Dale P; Newton GL; Aguilera JA; Fahey RC
Carcinogenesis; 1995 Apr; 16(4):767-74. PubMed ID: 7728953
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of fotemustine (Muphoran) cytotoxicity by amifostine in malignant melanoma cell lines.
Merlin JL; Marchal S; Ramacci C; Berlion M; Poullain MG
Anticancer Drugs; 2002 Feb; 13(2):141-7. PubMed ID: 11901306
[TBL] [Abstract][Full Text] [Related]
32. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
Boven E; Verschraagen M; Hulscher TM; Erkelens CA; Hausheer FH; Pinedo HM; van der Vijgh WJ
Eur J Cancer; 2002 May; 38(8):1148-56. PubMed ID: 12008205
[TBL] [Abstract][Full Text] [Related]
33. A method for the combined measurement of ethiofos and WR-1065 in plasma: application to pharmacokinetic experiments with ethiofos and its metabolites.
Swynnerton NF; Huelle BK; Mangold DJ; Ludden TM
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1495-9. PubMed ID: 3019967
[TBL] [Abstract][Full Text] [Related]
34. Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma.
McKibbin T; Panetta JC; Fouladi M; Gajjar A; Bai F; Okcu MF; Stewart CF
Clin Cancer Res; 2010 Feb; 16(3):1049-57. PubMed ID: 20103669
[TBL] [Abstract][Full Text] [Related]
35. Manganese superoxide dismutase (SOD2)-mediated delayed radioprotection induced by the free thiol form of amifostine and tumor necrosis factor alpha.
Murley JS; Kataoka Y; Baker KL; Diamond AM; Morgan WF; Grdina DJ
Radiat Res; 2007 Apr; 167(4):465-74. PubMed ID: 17388698
[TBL] [Abstract][Full Text] [Related]
36. A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
Gradishar WJ; Stephenson P; Glover DJ; Neuberg DS; Moore MR; Windschitl HE; Piel I; Abeloff MD
Cancer; 2001 Nov; 92(10):2517-22. PubMed ID: 11745184
[TBL] [Abstract][Full Text] [Related]
37. Human pharmacokinetics of WR-2721.
Shaw LM; Turrisi AT; Glover DJ; Bonner HS; Norfleet AL; Weiler C; Kligerman MM
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1501-4. PubMed ID: 3019968
[TBL] [Abstract][Full Text] [Related]
38. Amifostine and chemotherapy-related thrombocytopenia.
Budd GT
Semin Oncol; 1996 Aug; 23(4 Suppl 8):49-52. PubMed ID: 8783667
[TBL] [Abstract][Full Text] [Related]
39. Cardioprotection of rat heart myocytes with amifostine (Ethyol) and its free thiol, WR-1065, in vitro.
Dorr RT; Lagel K; McLean S
Eur J Cancer; 1996; 32A Suppl 4():S21-5. PubMed ID: 8976818
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of spontaneous metastases formation by amifostine.
Grdina DJ; Kataoka Y; Murley JS; Hunter N; Weichselbaum RR; Milas L
Int J Cancer; 2002 Jan; 97(2):135-41. PubMed ID: 11774255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
